China Sky One Medical, Inc. Announces Tianlong Subsidiary to Focus R&D Efforts on Antibiotics and Cardiac Drugs

Jan 21, 2010, 09:00 ET from China Sky One Medical, Inc.

HARBIN, China, Jan. 21 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "he Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that Heilongjiang Tianlong Pharmaceutical Company ("Tianlong"), the Company's wholly owned subsidiary, will change its R&D focus from external use medicines to antibiotics and cardiac drugs.

The change in Tianlong's R&D strategy is designed to build a solid foundation for the Company's future growth. Tianlong possesses one of the most complete portfolios of external use medicines in China. By focusing on the development of antibiotics and cardiac drugs, China Sky One Medical expects that Tianlong will be able to benefit from the increasing demand for prescription drugs as basic medical insurance coverage expands in China. Antibiotics represent the largest drug category in China, accounting for 20%-25% of total sales of western medicines. Medicines for the treatment of cardiac diseases represent the third largest drug category following cancer drugs, and account for roughly 15% of total sales of chemical medicines in China.

The Company plans to introduce five new antibiotics including Cefmetazole Sodium for injection, Cefodizime Sodium for injection, Aztreonam for injection, Teicoplanin for injection, Voriconazole Powder Solution for infusion, and two cardiac drugs, Amrinone for injection and Milrinone for injection. The Company has completed a feasibility analysis and experimental research, and has mastered the production technology. As a result of this initiative, China Sky One Medical will strengthen its distribution channel for prescription drugs by engaging more qualified commercial medical companies.

"We look forward to more breakthroughs in the development of antibiotics and cardiac drugs and will strive to obtain final SFDA approvals for the production of our seven new drugs as soon as possible," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "The demand for better health care and drugs is increasing rapidly, and we see this as an opportunity to capitalize on the growth of China's fragmented pharmaceutical industry."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include expectations of future growth or information regarding the impact of new research and development strategy. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
    China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-8703-2617

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915

     Mr. R. Micchelli, Sr. Financial Writer
     Tel:   +1-646-454-4516

SOURCE China Sky One Medical, Inc.